RSV MAT 60 µg

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Respiratory Syncytial Virus Infections

Drug Information

Target Indication

Respiratory Syncytial Virus Infections

Clinical Trial

Last updated: 2/4/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Related Pipeline

Acute Coronary Syndrome

Dental Caries

Thromboembolism

Pulmonary Disease, Chronic Obstructive

Hepatitis B